Trial Profile

Phase II Randomized Trial of MEK Inhibitor MSC1936369B or Placebo Combined With Gemcitabine in Metastatic Pancreas Cancer Subjects

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 25 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pimasertib (Primary) ; Gemcitabine
Indications Adenocarcinoma; Pancreatic cancer
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Sponsors Merck KGaA; Merck Serono

Most Recent Events

19 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
21 Aug 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
05 Dec 2012 Planned End Date changed from 1 Mar 2015 to 1 Aug 2015 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com